Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
ThinkAdvisor

Life Health > Life Insurance

ING: Ignore erroneous filing on $1.2B US share sale

X
Your article was successfully shared with the contacts you provided.

(Bloomberg) — ING Groep NV, the biggest Dutch financial-services company, told investors to disregard a regulatory filing that outlined plans to sell more shares in its U.S. life insurance unit.

“It was an error,” Raymond Vermeulen, an ING spokesman, said by phone. “Anything in the filing which says something about what we might be doing should be ignored.”

The U.S. Securities and Exchange Commission filing was posted before 7 a.m. in New York. More than an hour later, the Amsterdam-based company issued a statement saying the document was “filed prematurely and erroneously with regards to the potential sale of shares of ING US” and that the information should be “ignored until further notice.”

The parent company said in the erroneous release that it planned to sell 33 million shares of New York-based ING U.S. Inc. That holding would be valued at about $1.2 billion, based on yesterday’s closing price of $35.60 for ING U.S.

ING is exiting its U.S. life insurance business to comply with terms of a 2008 bailout. The Dutch company cut its stake last year to 57 percent through sales including an initial public offering in May when the stock sold for $19.50 apiece. According to the premature filing, the plan was to lower the stake to about 45 percent.

The parent company climbed 1.2 percent at 1:51 p.m. in Amsterdam trading.


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.